20.86  0.37 (1.81%)		06-12 16:00
Open: 20.67 High: 20.885 Volume: 6,283,610		Pre. Close: 20.49 Low: 20.25 Market Cap: 10,774(M)

Short term
Mid term
Targets	6-month :	24.5	1-year :	28.62
Resists	First :	20.97	Second :	24.5
Pivot price	19.41
Supports	First :	18.57	Second :	17.08
MAs	MA(5) :	20.18	MA(20) :	19.11
	MA(100) :	18.65	MA(250) :	21.19
MACD	MACD :	0.6	Signal :	0.4
%K %D	K(14,3) :	85.4	D(3) :	84
RSI	RSI(14): 70.7
52-week	High :	31.49	Low :	15.72

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BAX ] has closed above the upper band by 1.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 3.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	20.89 - 20.96	20.96 - 21.03
Low:	20.04 - 20.13	20.13 - 20.22
Close:	20.71 - 20.84	20.84 - 20.96

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Fri, 12 Jun 2026
Baxter (BAX) Has an Installed-Base-and-Margin-Reset Story Bigger Than a Turnaround Trade - AlphaStreet

Thu, 11 Jun 2026
Is Baxter International Inc. (BAX) A Good Stock To Buy Now? - Insider Monkey

Wed, 10 Jun 2026
Why Baxter International Inc (BAX) May Struggle to Outperform: A Look at Future Challenges - GuruFocus

Wed, 10 Jun 2026
Baxter International (BAX) Faces Tough Road Ahead, Says Citi in Downgrade - Yahoo Finance

Tue, 09 Jun 2026
Baxter International Inc (BAX) Shares Surge 4.1% -- What GF Scor - GuruFocus

Mon, 08 Jun 2026
Baxter International Inc. (BAX): Investor Outlook Shows 11.15% Potential Upside Amid Healthcare Sector Dynamics - DirectorsTalk Interviews

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	516 (M)
Shares Float	514 (M)
Held by Insiders	0.3 (%)
Held by Institutions	106.6 (%)
Shares Short	40,350 (K)
Shares Short P.Month	37,530 (K)

EPS	-1.91
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	11.69
Profit Margin	-9.7 %
Operating Margin	6 %
Return on Assets (ttm)	2.8 %
Return on Equity (ttm)	-15.1 %
Qtrly Rev. Growth	2.9 %
Gross Profit (p.s.)	7.58
Sales Per Share	21.91
EBITDA (p.s.)	3.69
Qtrly Earnings Growth	0 %
Operating Cash Flow	1,250 (M)
Levered Free Cash Flow	901 (M)

PE Ratio	-10.93
PEG Ratio	36.6
Price to Book value	1.78
Price to Sales	0.95
Price to Cash Flow	8.61

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.